CapsoVision stock
CVNASDAQCapsoVision, Inc., HealthcareISIN US1409351079
41Score 41 out of 100, Weak
Price and trend
55 / 100
Price history
+13% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.7% below it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 57% below its 52-week high. Largest decline in 1 year: 68% (December 2025 to February 2026).
Chart figures for advanced users
- SMA 50$6.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.64
- The lowest closing price of the last twelve months.
- Resistance$14.42
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CapsoVision, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $333.63M, is number 87 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $13.55M (up 15.3% year on year) and a loss of $25.32M.
- MEQIRI Score 41 out of 100 (Weak): rank 536 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $9.08M, financial debt $687K.Stability 69
Weaknesses
- Loss-makingLoss of $29.83M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 98% a year over the last 12 months.Stability 69
- Negative free cash flowFree cash flow −$27.89M over the last 12 months.Fundamentals 20
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 11% on the twelve months before. Revenue has grown strongly since 2023, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating −188%, net −187%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported −$0.15 (expected −$0.15)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.560.0%
- Revenue
- $14.78M0.0%
- Earnings per share
- −$0.450.0%
- Revenue
- $19.28M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.8%Revenue in the second half is expected to be higher than in the first half; the business is progressing as expected, with no numerical guidance.
“As such, we expect revenue in the second half of the year to be higher than in the first half.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $16.01M in total. One insider sold, $8,587 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at CapsoVision
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Metall ZugMETN.SW $460.48M38
- NeuroPaceNPCE $429.74M34
- CerusCERS $428.14M36
- ImplanticaIMP-A-SDB.ST $393.83M49
- StratecSBS.DE $353.7M52
- Treace Medical ConceptsTMCI $331.73M48
- SS Innovations InternationalSSII $302.72M28
- InfuSystem HoldingsINFU $300.35M69
ETFs that hold CapsoVision
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.